Pharmafile Logo
Pharmafocus logo
Advanced Search

Abbott

Showing 15 posts of 102 posts found.

Lonza picture

Lonza to make Elan’s Alzheimer’s candidate

December 7, 2011
Manufacturing and Production Abbott, Elan, Lonza

Elan has awarded a manufacturing contract to Lonza to supply the active pharmaceutical ingredient (API) for its small-molecule candidate Alzheimer’s …

News
Abbott picture

Abbott expands diagnostic pact with GlaxoSmithKline

November 29, 2011
Research and Development, Sales and Marketing Abbott, Cancer, GSK, non-small cell lung cancer

Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate.   This is an expansion of a …

News
Depakote

Abbott to pay $1.3 billion for Depakote lawsuits

October 24, 2011
Research and Development, Sales and Marketing Abbott, Depakote

 

News

Abbott spin-off could attract mega merger

October 21, 2011
Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche

Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …

News
Abbott

Abbott to split into two separate companies

October 20, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Abbott, Abbott Laboratories

Abbott’s management has decided to split the company into two separate entities in order to give shareholders a ‘distinct investment …

News

New MS drug shows promise for Abbott

August 10, 2011
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

News
Abbott's Humira (adalimumab)

Abbott wins $1.7bn Humira case

February 24, 2011
Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis

Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …

News

Abbott hep C drug ABT-450/r impresses in mid-stage trial

November 2, 2010
Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C

Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …

News

Abbott withdraws anti-obesity drug amid safety worries

October 11, 2010
Sales and Marketing Abbott, Meridia, obesity

Abbott has pulled its anti-obesity drug Meridia in the US after recent trials showed it increased the risk of stroke …

News

Recipharm buys Abbott plant to enter Spanish market

October 5, 2010
Manufacturing and Production Abbott, Recipharm, Solvay

Swedish contract development and manufacturing services company Recipharm has agreed to buy a facility in Parets del Valles, Spain, from …

News
Abbott Park

Abbott’s Meridia ‘increases heart attack risk’

September 2, 2010
Sales and Marketing Abbott, Meridia, drug safety

Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …

News

Abbott boosted by Solvay integration

July 22, 2010
Sales and Marketing 2010 financials, Abbott, Q2, Solvay

Abbott has posted a set of strong sales for the second quarter, buoyed by the integration of Solvay Pharmaceuticals and …

News

Olivier Bohuon joins Pierre Fabre

July 16, 2010
Sales and Marketing Abbott, Pierre Fabre, appointment, sales and marketing

Olivier Bohuon is to replace Jean-Pierre Garnier as the head of French pharma company Pierre Fabre from September. Bohuon is …

Appointment

Abbott and Daiichi Sankyo acclaimed in great places to work survey

May 31, 2010
Business Services Abbott, Daiichi Sankyo

The Great Place to Work Institute has named Abbott as one of the Top 50 Best Workplaces in the UK, …

News
Abbott sign

Abbott starts head-to-head MS trial

May 25, 2010
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab

Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …

News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026